Trial Profile
Adjuvant Chemotherapy Trial of S-1 for breast cancer with ER-positive and HER2-negative
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms POTENT
- 01 Jan 2021 Interim result (Data cut off 31 Jan 2019, n=1930) published in the Lancet Oncology.
- 31 May 2020 Results (n=1897) assessing estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 14 Dec 2019 Primary endpoint (Invasive Disease-free survival) has been met as per results presented at the 42nd Annual San Antonio Breast Cancer Symposium